Previous close | 88.66 |
Open | 88.11 |
Bid | 88.23 x 800 |
Ask | 88.28 x 1300 |
Day's range | 87.93 - 88.42 |
52-week range | 77.04 - 98.52 |
Volume | 495,139 |
Avg. volume | 2,024,393 |
Market cap | 199.359B |
Beta (5Y monthly) | 0.51 |
PE ratio (TTM) | 25.09 |
EPS (TTM) | 3.52 |
Earnings date | N/A |
Forward dividend & yield | 3.20 (3.61%) |
Ex-dividend date | 04-Mar-2021 |
1y target est | 104.67 |
Novartis (NVS) enters into an agreement with Roche for the manufacturing of the active pharmaceutical ingredient (API) for Actemra/RoActemra.
Novartis (NVS) enters a three-year collaboration with Artios to strengthen its radiogland therapies pipeline.
The European Commission approves Novartis' (NVS) Kesimpta for the treatment of adult patients with relapsing forms of multiple sclerosis.